Semaglutide & Tirzepatide in Lubbock, Texas – What you need to know!

By: Katie Brandon


We love the providing our patients with the options for the best resources for losing weight, including sourcing the best and most affordable medication! Did you know that Semaglutide and Tirzepatide are currently the most effective weight loss medications on the market? At Ignite in Lubbock, Texas we have affordable options for patients who are on these medications currently or who are wanting to start them for weight loss. 

Brand-name Ozempic®, Wegovy®, Mounjaro®, and Zepbound® are pre-filled syringes of GLP-1’s that are excellent for weight loss and diabetes. Wegovy® and Zepbound® are FDA approved for weight loss while Ozempic® and Mounjaro® are FDA approved for diabetes. What you need to know is that the makers of the drugs are different and dosages many vary but the ingredients are the SAME. Wegovy® = Ozempic®. Tirzepatide® = Zepbound®. Often, these drugs require a prior authorization from your insurance. These drugs can be difficult to find as they are in a shortage due to high demand. 

Other options we give our patients are utilizing compounding pharmacies for Tirzepatide and Semaglutide salts. An important difference with these compounded medications is that FDA does not verify the safety, effectiveness or quality of compounded drugs – instead the compounding pharmacy does. Another important difference is that these compounding pharmacies mix in B12, or other additives, to help with side effects such as nausea.

At Ignite, we work with our patients to offer medications that make the most sense for them medically and financially. If a patient has insurance coverage for Wegovy®, we happily submit prior authorizations for them. If insurance excludes a patient from weight loss medication coverage, compounded medications may be a better fit. We have prescribed both for our patients with EXCELLENT results.  

* All information subject to change. Images may contain models. Individual results are not guaranteed and may vary.